Bromodomain and extra-terminal (BET) inhibitors suppress super-enhancers and show cytotoxicity against multiple types of tumors. However, early clinical trials with BET inhibitors showed severe hematopoietic toxicities, highlighting the need for sensitive tumors and rational combination strategies to enhance their therapeutic potential. Here, we identified colon cancer-specific super-enhancers that were associated with multiple oncogenic pathways, including the mitogen-activated protein kinase (MAPK) signaling pathway.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rCNkph
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Publication date: Available online 6 January 2018 Source: Current Problems in Diagnostic Radiology Author(s): Mark D. Kovacs, Maximilian...
-
Background Chronic rhinosinusitis (CRS) is a commonly observed sequela after radiation therapy to the paranasal sinuses. The histopatholo...
-
Abstract Purpose Currently, intraoperative ultrasound in brain tumor surgery is a rapidly propagating option in imaging technology. We e...
-
Publication date: Available online 6 November 2017 Source: Academic Radiology Author(s): Steven J. Esses, Samir S. Taneja, Andrew B. Ros...
-
Publication date: Available online 4 November 2017 Source: Current Problems in Diagnostic Radiology Author(s): Elisabeth R. Garwood, Gre...
-
To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidiscip...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου